Selpercatinib in Solid or CNS tumors with RET-Alterations
Contact
Description
Eligibility and criteria
IRB Number:
19-016024
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
- Be given selpercatinib to take in the clinic and at home
- Complete frequent clinic visits at CHOP
- Have frequent blood tests, including research blood tests to measure selpercatinib levels (pharmacokinetic studies), hormone levels, and tests to measure genetic material in your blood
- Have periodic EKGs
- Have periodic imaging performed to evaluate your response to treatment, evaluate your growth plate (if you are not at full adult height)
- Have a dental evaluation (if you are ⥠5 years old)
- Have a puberty maturation evaluation (if you are ⥠7 years old)
- Be asked to complete questionnaires and medication diaries
- Be asked if we can submit previously obtained samples of your tumor to the sponsor; this will not require new biopsy
- Be asked if we can obtain a small sample of cerebrospinal fluid (CSF) if collected as part of your regular cancer care Â
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.